This work, comprising of a combination of biochemical and computational approaches, could represent a rational guideline for further structural modifications of 2,4-dihydroindeno[1,2-c]pyrazoles to generate a new class of EGFR TKIs for NSCLC therapy. Here, EGFR is linked to non-small cell lung carcinoma.